Loading...
Loading...
SPRB| Name | Value |
|---|---|
| Revenues | 2.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | 1.9M |
| Operating Expense | 15.2M |
| Operating I/L | -13.2M |
| Other Income/Expense | 0.4M |
| Interest Income | 0.5M |
| Pretax | -12.8M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -12.5M |
Spruce Biosciences, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare endocrine disorders. The company's primary focus is on advancing tildacerfont, a non-steroidal therapy designed to improve disease management and reduce steroid dependency in adult patients with congenital adrenal hyperplasia (CAH). Additionally, Spruce Biosciences is conducting clinical trials for tildacerfont's potential application in pediatric CAH and polycystic ovary syndrome. The company also holds a license agreement with Eli Lilly and Company for the research, development, and commercialization of pharmaceutical compounds.
